RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results

RBC Capital analyst Randall Stanicky reiterated an Outperform rating and $22 price target on Kempharm (NASDAQ: KMPH) as new KP201 abuse-deterrent data add further support to product differentiation.

Stanicky commented, "This morning, KMPH released results of three tamper studies which showed KP201 holding up well against the many manipulation techniques used to extract hydrocodone for abuse. KP201 continues to show differentiation against the various tamper-resistant technologies available, and we anticipate positive results from the second intranasal abuse study in the coming weeks and an NDA filing in 4Q2015."

For an analyst ratings summary and ratings history on Kempharm click here. For more ratings news on Kempharm click here.

Shares of Kempharm closed at $18.17 yesterday.

You May Also Be Interested In

• RBC Capital Starts Cencora Inc (COR) at Sector Perform
• TD Cowen Upgrades BRP Inc. (DOO:CN) (DOOO) to Buy
• Rothschild Redburn Starts ResMed (RMD) at Neutral